Literature DB >> 20558417

Cholinergic imaging in corticobasal syndrome, progressive supranuclear palsy and frontotemporal dementia.

Shigeki Hirano1, Hitoshi Shinotoh, Hitoshi Shimada, Akiyo Aotsuka, Noriko Tanaka, Tsuneyoshi Ota, Koichi Sato, Hiroshi Ito, Satoshi Kuwabara, Kiyoshi Fukushi, Toshiaki Irie, Tetsuya Suhara.   

Abstract

Corticobasal syndrome, progressive supranuclear palsy and frontotemporal dementia are all part of a disease spectrum that includes common cognitive impairment and movement disorders. The aim of this study was to characterize brain cholinergic deficits in these disorders. We measured brain acetylcholinesterase activity by [11C] N-methylpiperidin-4-yl acetate and positron emission tomography in seven patients with corticobasal syndrome (67.6+/-5.9 years), 12 with progressive supranuclear palsy (68.5+/-4.1 years), eight with frontotemporal dementia (59.8+/-6.9 years) and 16 healthy controls (61.2+/-8.5 years). Two-tissue compartment three-parameter model and non-linear least squares analysis with arterial input function were performed. k3 value, an index of acetylcholinesterase activity, was calculated voxel-by-voxel in the brain of each subject. The k3 images in each disease group were compared with the control group by using Statistical Parametric Mapping 2. Volume of interest analysis was performed on spatially normalized k3 images. The corticobasal syndrome group showed decreased acetylcholinesterase activity (k3 values) in the paracentral region, frontal, parietal and occipital cortices (P<0.05, cluster corrected). The group with progressive supranuclear palsy had reduced acetylcholinesterase activity in the paracentral region and thalamus (P<0.05, cluster corrected). The frontotemporal dementia group showed no significant differences in acetylcholinesterase activity. Volume of interest analysis showed mean cortical acetylcholinesterase activity to be reduced by 17.5% in corticobasal syndrome (P<0.001), 9.4% in progressive supranuclear palsy (P<0.05) and 4.4% in frontotemporal dementia (non-significant), when compared with the control group. Thalamic acetylcholinesterase activity was reduced by 6.4% in corticobasal syndrome (non-significant), 24.0% in progressive supranuclear palsy (P<0.03) and increased by 3.3% in frontotemporal dementia (non-significant). Both corticobasal syndrome and progressive supranuclear palsy showed brain cholinergic deficits, but their distribution differed somewhat. Significant brain cholinergic deficits were not seen in frontotemporal dementia, which may explain the unresponsiveness of this condition to cholinergic modulation therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20558417     DOI: 10.1093/brain/awq120

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  21 in total

Review 1.  Recent advances in the diagnosis and treatment of balance disorders.

Authors:  Klaus Jahn; Marianne Dieterich
Journal:  J Neurol       Date:  2011-10-27       Impact factor: 4.849

Review 2.  PET/CT in diagnosis of movement disorders.

Authors:  Valentina Berti; Alberto Pupi; Lisa Mosconi
Journal:  Ann N Y Acad Sci       Date:  2011-06       Impact factor: 5.691

3.  Reproducible network and regional topographies of abnormal glucose metabolism associated with progressive supranuclear palsy: Multivariate and univariate analyses in American and Chinese patient cohorts.

Authors:  Jingjie Ge; Jianjun Wu; Shichun Peng; Ping Wu; Jian Wang; Huiwei Zhang; Yihui Guan; David Eidelberg; Chuantao Zuo; Yilong Ma
Journal:  Hum Brain Mapp       Date:  2018-03-13       Impact factor: 5.038

Review 4.  Neurophysiology and neurochemistry of corticobasal syndrome.

Authors:  Aditya A Murgai; Mandar S Jog
Journal:  J Neurol       Date:  2018-01-06       Impact factor: 4.849

Review 5.  Reassessment of the role of the central cholinergic system.

Authors:  Anna Hrabovska; Eric Krejci
Journal:  J Mol Neurosci       Date:  2013-11-10       Impact factor: 3.444

6.  Diagnosis and treatment of corticobasal degeneration.

Authors:  Melissa J Armstrong
Journal:  Curr Treat Options Neurol       Date:  2014-03       Impact factor: 3.598

Review 7.  Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management.

Authors:  Rachel E Seltman; Brandy R Matthews
Journal:  CNS Drugs       Date:  2012-10-01       Impact factor: 5.749

Review 8.  New insights into atypical parkinsonism.

Authors:  Gregor K Wenning; Florian Krismer; Werner Poewe
Journal:  Curr Opin Neurol       Date:  2011-08       Impact factor: 5.710

Review 9.  Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?

Authors:  Jennifer L Whitwell; Günter U Höglinger; Angelo Antonini; Yvette Bordelon; Adam L Boxer; Carlo Colosimo; Thilo van Eimeren; Lawrence I Golbe; Jan Kassubek; Carolin Kurz; Irene Litvan; Alexander Pantelyat; Gil Rabinovici; Gesine Respondek; Axel Rominger; James B Rowe; Maria Stamelou; Keith A Josephs
Journal:  Mov Disord       Date:  2017-05-13       Impact factor: 10.338

Review 10.  Molecular Imaging of Extrapyramidal Movement Disorders With Dementia: The 4R Tauopathies.

Authors:  Kirk A Frey
Journal:  Semin Nucl Med       Date:  2021-01-08       Impact factor: 4.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.